å»è¬åå ¬è¡šãããæŽå¯
é»ç±ã¯ãäºé²æ¥çš®ãé²ãããšãã§ããææããèã®å¬å·ã«ãã£ãŠåŒãèµ·ããããæµè¡ã®åŸåã«ããç æ°ã§ãã é»ç±ã¯ãææããè(ãšã€ãã¹ãšãããŽã¬ã¹)ã«ãã£ãŠããã«åºãããèãããããŸãã¯ä»ã®é¢ç¯çãªã©ã®ãã¯ãã«ã«ãã£ãŠãã¢ã«ããŠã€ã«ã¹(ãŠã€ã«ã¹ãåºãã)ã«ãã£ãŠåŒãèµ·ããããŸãã ãããã®èã¯å®¶ã森ããžã£ã³ã°ã«ããŸãã¯äž¡æ¹ã®çæ¯å°ã§ç¹æ®ããŸãã é»ç±ã¯ãã°ããŒãã«ã«åºããå±éºæ§ã®ããé«è åšçŸæ£ã§ãããã°ããŒãã«ãã«ã¹ã»ãã¥ãªãã£ãžã®è åšãæç€ºããŸãã é»ç±ã®äžè¬çãªçç¶ã¯ãé çãç±ãåãæ°ãååãå«ãŸããŸãã éçäŸã§ã¯ãé»ç±ãå¿èãè èãèèãªã©ã®èåšã«åœ±é¿ãåãŒãå¯èœæ§ããããŸããäžççãªé»ç±åŠ... ãã£ãšèŠã
ç±³åœOTCç¹çŒè¬åžå Žã補åå¥ïŒSystaneãRefreshãBlinkãTheraTearsãRohtoããã®ä»ïŒãããã±ãŒãžã³ã°ã¿ã€ãå¥ïŒè€æ°åçšéããã«ãäœ¿ãæšãŠãã€ã¢ã«ïŒãé²è å€ã¹ããŒã¿ã¹å¥ïŒé²è å€å«æãé²è å€ããªãŒïŒãã¯ãŒã«ã¿ã€ãã¹ããŒã¿ã¹å¥ïŒã¯ãŒã«ããã³ã¯ãŒã«ïŒãæµéãã£ãã«å¥ïŒå°å£²è¬å±ããã³ãã©ãã°ã¹ãã¢ãé»ååååŒããã³ãªã³ã©ã€ã³ïŒ è¬å±ãã¹ãŒããŒããŒã±ããããã³ãã€ããŒããŒã±ãããçŒç§ã¯ãªããã¯ããã®ä»)... ãã£ãšèŠã
ãã¢ã€ãè «çã¯ãæªæ§ã§ã¯ãªãçµåçµç¹ã®æé·ã§ãã ãã¹ã¢ã€ãè «çã¯ãéåžžãè ãèãè ¹ã«çºéããŸãã ãã¢ã€ãè «çãç©æ¥µçãªç·ç¶è «çãšåŒã°ããŸãã è «çããã£ãããšæé·ããããã«æ²»çããå¿ èŠã¯ãããŸããã ãã®ä»ã¯æé·ã®æ¥éãªçããããå€ç§ãååŠçæ³ãæŸå°ç·çæ³ããŸãã¯ä»ã®è¬ç©ãšæ±ãããŸããäžçã®ãããè «çåžå Žã¯ãè©äŸ¡ããããšæšå®ããã US$ 2,494.1 çŸäžå ãåãåãã 2022幎 å±ç€ºäºå® ã«ã°ã¬ ã«ã€ã㊠7.3%(çšæ) äºå ±æéäž (2022-2030).å³1.ã°ããŒãã«ãããè «çåžå Žã·ã§ã¢(%)ãè¬ç©ã®çš®é¡ã2022ã°ããŒãã«ãããè «çåžå Ž - ãã©ã€ã㌠ãã¢ã€ãè «çã®æ²»... ãã£ãšèŠã
äžççãªç£å» ãã«ã¹ã±ã¢åžå Žãè©äŸ¡ãããŸããUS$30,368.5 Mn2021幎(æå20幎)ã«äŸ¡å€ã®å°éãäºæž¬US$ 55,657.5 ã¡ãŒãã«ã«ãã£ãŠ2028幎ãåãåãã9.0%ã®CAGR éã®è·é¢2022幎ã2028幎ãåãåãã äžççãªç£å»å»çåžå Žã¯ãäžçäžã®èгè³ãé»é垯ççŸæ£ã®çœ¹æ£çã®å¢å ãæ¿åºãåç©çŠç¥åäŒã®æå©ãªåãçµã¿ã«ãã匷åãªæé·ãçµéšããŠããŸãã ãŸããåç©å»çã«çŠç¹ãåããããã³ãããã¯äžã«ãããã®æ¡çšã®å¢å ãæåŸ ãããåžå Žã®æé·ãä¿é²ããŸãã ããããåç©å»çãµãŒãã¹ã»ãœãªã¥ãŒã·ã§ã³ã®é«ã³ã¹ãããåœé åãå»è¬åã®å¯çšæ§ãªã©ã®èŠå ã¯ãåžå Žã®æé·ã劚ããããšãæåŸ ã... ãã£ãšèŠã
Intravenouså ç«ã°ãããªã³(IVIG)ã¯å ç«æåãé åããæ£è ã®æ²»çã§ãã IVIGã¯ãæ°å人ã®å¥åº·ãªå¯ä»è ã®è¡æŒ¿ããåŸãããå ç«ã°ãããªã³(æäœ)ã®ã³ã¬ã¯ã·ã§ã³ã§ããå ç«ã°ãããªã³ã¯ãææçãšã®æŠããæ¯æŽããããã«å¥åº·ãªäººã ã®å ç«ã·ã¹ãã ã«ãã£ãŠçæãããã¿ã³ãã¯è³ªã§ãã IVIGã¯è¡æŒ¿(è¡æ¶²è£œå)ããæŽŸçããŠããéãè¡æ¶²åªä»ææãåèšããå±éºæ§ã¯éåžžã«äœãããšã§ããIVIGã¯ãæ°æéãããéèå æ³šå ¥(è ã®éè)ãšããŠæäžãããå®äºããŸãã æ³šå ¥ã®é »åºŠã¯æ£è ã®å¿ èŠæ§ã«ãã£ãŠå€ãããŸããç±³åœéèå å ç«ã°ãããªã³åžå Ž - ã³ãããŠã€ã«ã¹ã®åœ±é¿(COVID-19)ãã³ãããã¯ã³ãããŠã€ã«... ãã£ãšèŠã
Vernal keratoconjunctivitis (VKC)ã¯ã¢ã¬ã«ã®ãŒæ§ã®ç®ã®ç æ°ã§ãã ããã¯ç¹ã«åäŸã«ç·æ§ã«ãäž»ã«åœ±é¿ãäžããå€å åã®Th2现èåªä»ãããæ¥åã®è¡šé¢ã®ççç¶æ ã§ãã æ¿ããããã¿ãçãããå ææçããã³æ¶ã¯æãäžè¬çãªçç¶ã§ãã æãäžè¬çãªå åã¯ãçµææ§é«è¡çãè¡šé¢æ§è§èçãããã³å·šå€§ãªè¿ç±ã§ãã ãã¹ã现èãTh2现èãã·ããããeosinophilsãä»çååãååŠãããã³ã·ãããã®éå°çºçŸã¯ãå èè§èçã®ç¹åŸŽã§ãã çµææµžå ¥ãå å©çŽãçµæç·ç¶å¢æ®ç å€ããã³çµèæ§é«è¡çã¯ãè ç®èçã®ç¹åŸŽã§ãã æ··åãpalpebralãããã³limbalã¯ãä¹³é ã®åå¿ã®äž»ãªè§£... ãã£ãšèŠã
Mesalazineã¯é©åºŠã«æŽ»åçãªæœ°çæ§è¡çªã«ç©ããã«æ±ãã®ã«äœ¿çšãããaminosalicylateã®è¬å€ã§éæãããäžåºŠå¯è§£ãç¶æããŸãã Mesalazineã¯æççå€ã§ããµã«ãã©ãŒé žå¡©ããã³éã¹ããã€ãã®æççè¬ãšæ§é çã«é¢é£ããŠããŸãã¢ã»ãã«ãµãªãã«é žã®ãããªãæœ°çæ§å€§è žçŸæ£ãã¯ããŒã³ç ãªã©ã®ççæ§è žçŸæ£ã®æ²»çã«äœ¿çšãããŸãã æœ°çæ§é¢ç¯ç å€§è žã©ã€ãã³ã°(ã³ãã³)ã®ççãåŒãèµ·ããæ ¢æ§ççè žçŸæ£ã®äžçš®ã§ãã å€§è žã®ã©ã€ãã³ã°ã«æœ°çãçæããè¿ããã³ç²æ¶²ã®åºè¡ããã³æåºãåŒãèµ·ããå¯èœæ§ããããŸãã Mesalazineã¯ãè žå ã®çç(èµ€ã¿ãè «ã)ãæå¶ããèã®çã¿ãåºè¡ãªã©ã®çç¶... ãã£ãšèŠã
ãã©ãã°ããªããªãŒãšã¯ãè¬ç©ã®è§£æŸãšåžåã®ããã®ç®çã®èº«äœéšäœã«è¬ãæç€ºããããã«å©çšãããæè¡ãæããŸãã éŒ»è¬æäžã¯ãéèå æäžã«å¶éãããè¬ã®ç³»çµ±çãªå¯çšæ§ã®ããã®ä»£æ¿ã«ãŒããšããŠäœ¿çšãããŠããŸããã ããã¯ã¢ã¬ã«ã®ãŒæ§ããã³éã¢ã¬ã«ã®ãŒæ§éŒ»çã®åŠçœ®ã®ããã®ç®¡çã®æã奜ãŸããã«ãŒããçé çãèŠçããã³éŒ»ã®æ··éã®åŠçœ®ã¯éŒ»çãå ±éã®é¢šéªããŸãã¯å¯éŒ»çã«é¢é£ä»ããããŸãã 錻ã®ã«ãŒãã¯ãè¿ éãã€é«ç³»çµ±çãªå¯çšæ§ã錻è ããè³ã«çŽæ¥è¬ãã¿ãŒã²ãã£ã³ã°ããå¯èœæ§ãèã«ããæåã®ãã¹ä»£è¬ã®åé¿ãå«ãé©ãã¹ãå©ç¹ã瀺ããŠããŸãã Intranasalã®è¬å€é é(ã錻ã®è¬å€é é)ã¯æ²»ç广(ããŒã«ã«ãå šèº«... ãã£ãšèŠã
ã€ã³ããã·ã¢ã®äººã ãç¹ã«äžå¹Žäžä»£ã«ãããå¥åº·ç®¡çæèã®é«ãŸãã¯ãäºæž¬æéäžã®ã€ã³ããã·ã¢æ é€è£å©é£ååžå Žã®æé·ã«å¥œåœ±é¿ãäžãããšäºæ³ããããã€ã³ããã·ã¢ã®äººå£ã®50ïŒ ã¯30æ³æªæºã§ããããã®ãããªå·šå€§ãªè¥å¹Žäººå£ã¯ãå€å¿ãªã©ã€ãã¹ã¿ã€ã«ã«ããé£ç掻ã®å€åã«æ¯ãããããã¿ãã³ãµããªã¡ã³ãã®éèŠãæŒãäžãããšäºæž¬ãããŠãããã€ã³ããã·ã¢ã®æ é€è£å©é£ååžå Žã¯ãäºæž¬æéäžïŒ2021ïœ2028幎ïŒã«å¹Žå¹³åæé·ç7.7ïŒ ã瀺ãã2028幎æ«ãŸã§ã«å£²äžé«ã§31å7,751äžç±³ãã«ãçªç Žãããšäºæž¬ãããã æšé²èŠå å¥åº·ãšãŠã§ã«ããŒã€ã³ã°ã«é¢ããæèã®é«ãŸããšãã€ã³ããã·ã¢å šåã«ããããããã幎霢局ã§ã®å¥åº·... ãã£ãšèŠã
äžå€®è²ŽæãããŒãã£(CPP)ã¯ãgonadotropinã«äŸåããªãææ¥æãšåŒã°ããŸãã äºæ¬¡æ§çç¹åŸŽã®éçºãå éæé·ãããã³ææ¥æã®æ£åžžãªå¹Žéœ¢ã®åã«éªšã®æçã«ããææ¥æå€åã®çºçã«ãã£ãŠç¹åŸŽä»ããããå åæ³é¢é£ã®çºéçŸæ£ã§ã(8人ã®å°å¥³ãš9人ã®ç·ã®å)ããã®æ¡ä»¶ã¯ãidiopathicã§ãã ããããäžå€®ã®äºæããªãææ¥æã®æãäžè¬çãªéºäŒçåå ã¯ãMKRN3éºäŒåã«ãããå€ç°ã§ããã éºäŒåŠã«å ããŠãæ¡ä»¶ã«åœ±é¿ãåãŒãå¯èœæ§ã®ãããã®ä»ã®åœ±é¿èŠå ã«ã¯ãæ é€ã瀟äŒçµæžç¶æ ãããã³ç°å¢å ã®ç¹å®ã®ååŠç©è³ªãžã®æŽé²ãå«ãŸããŸããã°ããŒãã«ã»ã»ã³ãã©ã«ã»ãã¬ã³ãŒã¹ãã»ãããŒãã£ã»ããŒã±ãã - ã³ã... ãã£ãšèŠã
äžççãªæååºå€åžå Žã¯ã§è©äŸ¡ãããŸããUS$30,773.2 Mn2021幎ã¯äŸ¡å€ã®äŸ¡å€ã«éããèŠéãã§ãUS$ 57,337.5 ã¡ãŒãã«ã«ãã£ãŠ2028幎ãåãåãã9.4%ã®CAGRéã®è·é¢2022幎ã2028幎ãåãåãã æååºå€åžå Žã¯ãæ ¢æ§çŸæ£ã®å¢æ®ã«ãã匷çãªæé·ãçµéšããäžçäžã®æååºå€ã«å¯ŸããéèŠãé«ãŸããŸãã ãŸããäžçäžã«ãããæ°èŠæååºå€ã®éçºã«æ³šåããã²ãªã¢ããªã®äººå£å¢å ãæåŸ ãããŠããŸãã ããããªãããæååºè¬ãå³ããæ¿åºèŠå¶ã«é¢é£ããå¯äœçšãªã©ã®èŠå ã¯ãäžççãªæååºè¬åžå Žã®æé·ã劚ããããšãæåŸ ãããŸããã°ããŒãã«ã¢ã³ãååºå€åžå Ž: å°åã€ã³ãµã€ããžãªã°ã©ãã£... ãã£ãšèŠã
Dermatomyositisã¯éªšæ Œã®çè匱ãããã³ç®ã®å€æŽã«ãã£ãŠç¹åŸŽä»ããããidiopathicççã®myopathyã§ãã Dermatomyositisã¯ä»éããçºç¹ã«ãã£ãŠç¹åŸŽä»ããããŸãããŸãã¯ããé »ç¹ã«ãçè匱ãã®åã«ã æãäžè¬çãªçç¶ã¯çèã®åŒ±ããéåžžãäœã®ãã©ã³ã¯ã«æãè¿ããããã®çèã«åœ±é¿ãäžãã(proximal)ã§ãã çµå±ãæ£è ã¯ã座ã£ãäœçœ®ãéæ®µãç»ãããªããžã§ã¯ããæã¡äžãããããŸãã¯é äžã«éããã®ãå°é£ã§ãã å Žåã«ãã£ãŠã¯ãèå ã®çè(身äœã®å¹¹ã«è¿ããã®ã§ã¯ãªã)ãç æ°ã®çµéåŸã«åœ±é¿ãåããããšããããŸããã°ããŒãã«ç®èçè¬åžå Žãè©äŸ¡ããããšæšå®ããã U... ãã£ãšèŠã
婊人ç§ããå»è¬ååžå Ž ãµã€ãºãšäºæž¬ â 2026 â 2033äžççãªå©Šäººç§ããè¬åžå ŽèŠæš¡ã¯ã2026幎ã«14.3åç±³ãã«ã§è©äŸ¡ããã2033幎ãŸã§ã®9.5%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããUSD 27.9åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«å©Šäººç§ããè¬åžå Žã¯ãåå®®é žéšãåµå·£ãåå®®ãè ãããã³ãã«ããŒããã®äžççãªå¢å ã®çºççã«ãã£ãŠé§åããã广çãªæ²»çãªãã·ã§ã³ã®éèŠãå¢å ããæ©æèšºæããã³ã¹ã¯ãªãŒãã³ã°ããã°ã©ã ã®æèãé«ãŸããŸãã æšççæ³ãå ç«çæ³ããã³å人åãããè¬ã®é«åºŠåã¯åŠçœ®ã®çµæãæ¹åããæ²»çã®éžæãæ¡åŒµããŸãã æ°èŠå»è¬ååè£ã®å ç¢ãªãã€ãã©ã€ã³ãšå ±ã«ãè «çåŠ... ãã£ãšèŠã
ã°ããŒãã« Transthyretin Amyloidosis æ²»çåžå Ž â InsightséºäŒæ§ãã©ã³ã¹ãã¬ã³ã¢ããã€ãç(hATTR)ããã³éçåãã©ã³ã¹ãã¬ã³ã¢ããã€ãçã¯ããã©ã³ã¹ãã¬ã³ã¢ããã€ãçã®2ã€ã®äž»ãªã¿ã€ãã§ãã hATTR ã¯ãFamilial Amyloid Polyneuropathy (FAP) ããã³ Familial Amyloid Cardiomyopathy (FAC) ã«ããã«åé¡ãããŸãã ã¯ã€ã«ãåããªã¢ã³ã(ATTRwt)ã¯ãå¿ã«åªå çã«åœ±é¿ããŸããTransthyretinã®amyloidosisã¯ã¬ããŒã«ãã£ãŠäœãåºãããtransthyreti... ãã£ãšèŠã
äžççãªãã¹ã¿ãŒã®åºåã®ç®ã®ç¡ç§©åºã®åžå Žã¯ã§è©äŸ¡ãããŸããUS$ 28,360.6 Mn2021幎ã¯äŸ¡å€ã®äŸ¡å€ã«éããèŠéãã§ãUS$ 39,213.5 ã¡ãŒãã«ã«ãã£ãŠ2028幎ãåãåããCAGRã®5%éã®è·é¢2022幎ã2028幎ãåãåãã äžççãªèåŸè ã»ã°ã¡ã³ãã®ç®ã®é害åžå Žã¯ãèåŸã»ã°ã¡ã³ãã®ç®ã®é害ã®è² æ ã®å¢å ã«ãã匷åãªæé·ãçµéšããäžçäžã®å¹ŸäœåŠç(èå)人å£ã§äžæããŠããŸãã ãŸããå®å šã§å¹æçãªæ²»çã«å¯ŸããéèŠã®å¢å ããæ°ããªæ²»çã®éçºã«æ³šåããå¢å ãæåŸ ãããåžå Žã®æé·ãåŸæŒãããã ããããªãããå³ããèŠå¶æ çµã¿/å¯èœæ§ãçŒçŸæ£ã®ç¬¬äžæ¬¡ã€ã³ãã©ã®æ¬ åŠãªã©ã®èŠå ã¯ãåž... ãã£ãšèŠã
ã¬ãããªãªããµã«ãã®åŠçœ®ã®åžå Žã®ãµã€ãºããã³ äºæž¬ â 2026 â 2033äžçã® Retroperitoneal Liposarcomaã®åŠçœ®ã®åžå Žã®ãµã€ãºã¯ãããŸã 2026幎ã®USD 275,000,000ã§è©äŸ¡ãããæåŸ ããã 2033幎ãŸã§ã«USD 423çŸäžã«éããååç©ã®å¹Žéæé·çãå±ç€º 2026ïœ2033幎(CAGR) 6.7%ãããã£ãŒã«ã¬ããããªããªãã«ãªããµã«ãã®åŠçœ®ã®åžå Žã¯ã«ãã£ãŠé転ãããŸã ãŸããªæããããã£ãã·ã¥ã®sarcomasã®å¢å ã®çºçãå¢å ã®æè æ©æãã蚺æãšè «çåŠæ²»çã®é²æ© ã¢ãããŒãã 倿²æåŠåã®æŠç¥ã®æŽ»çš å€ç§ãæŸå°ç·çæ³ãå«ãã§ã ã¿ãŒã²ãã... ãã£ãšèŠã
ã²ãšæé·ãã«ã¢ã³åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎äžçã®äººéã®æé·ãã«ã¢ã³ã®åžå Žã®ãµã€ãºã¯è©äŸ¡ããããšæšå®ãããŸã 2026幎ã®USD 4.8åãã«ã§ãUSD 7.4åãã«ã«éããèŠèŸŒã¿ 2033幎ã2026幎ãã6.1%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€º 2033幎é ãããã£ãŒã«äººéã®æé·ãã«ã¢ã³(HGH) åžå Žã¯äžæã«ãã£ãŠé転ãããŸã æé·ãã«ã¢ã³ã®äžè¶³, ã¿ãŒããŒçå矀, æ ¢æ§çŸæ£ è èç çŸæ£ä»æé·é¢é£éå®³ã æ¡çšæ å ± æ©æèšºæãšæ²»çã®éžæè¢ã®èªèã¯ãéèŠãé«ãã çµæãã®ããã® HGH çæ³, ç¹ã«å°å ç§ããã³å€§äººã® å åæ³åŠã åŸæ¥ã®é害ãè¶ããé©çšãæ¡å€§ããŠäžããã ... ãã£ãšèŠã
人工çãªæµžé åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎ã°ããŒãã«äººå·¥æç²Ÿåžå ŽèŠæš¡ã¯ã 2026幎ã«USD 5.3åã§è©äŸ¡ãããUSD 9.6ã«éããèŠèŸŒã¿ 2033幎(æå20幎)ã«å¢æ®ç(CAGR)ã8.7%å¢ 2026幎ïœ2033幎ãããã£ãŒã«äººå·¥çãªæµžéã®åžå Žã¯å¢å ã«ãã£ãŠé転ãããŸã äžåŠçãé å»¶ã®å¹Œå°æãããã³æé·æèã®åªå é äœ åçæè¡(ART)ã®æ¯æŽ ç·æ§ãšç·æ§ã®ã©ã€ãžã³ã°ç 女æ§ã®çæ®äžèœãã®ãããªã©ã€ãã¹ã¿ã€ã«ã®èŠå ãšçµåããã ã¹ãã¬ã¹ãè¥æºãå«ç ã¯ãäžåŠçã«å¯ŸããèŠæ±ãçãããŠããŸã æ²»çã 粟ååŠçã®æè¡çãªé²æ©, åçµä¿åããã³äžåŠç£èŠã¯ããã·ãŒãžã£ãæ¹åããŸãã... ãã£ãšèŠã